Skip to main content
All lobbying filings

W STRATEGIES, LLC

Lobbying for ABBOTT LABORATORIES · A pharmaceuticals health care company.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 1

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Issues related to infant formula access. Issues related to DMEPOS reimbursement by CMS. H.R.2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.

 Bills named in this filing 1
  • H.R. 2300
    To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other pu…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem